Antiplatelet therapy has become the mainstay of secondary stroke prevention. Recurrence
risk after transient ischemic attack (TIA) or ischemic stroke ranges from 5% to 20% per year …

Stroke is one of the leading causes of disability; most are due to atherothrombotic
mechanisms. About one third of ischemic strokes are preceded by other stroke or transient …

Antiplatelet therapy plays a major role in recurrent stroke prevention (1, 2). During the past
30-plus years, we have witnessed the emergence of four major antiplatelet agents for …

Background: Stroke risk is heightened among patients who have had a primary stroke or
transient ischaemic attack (TIA). The primary care physician is in the best position to monitor …

Since the publication of the Antiplatelet Trialists Collab-oration meta-analyses well over a
decade ago1 showing a relative risk reduction of 25% from aspirin for all secondary vascular …

Secondary stroke prevention is a challenge, and there is continual pursuit to investigate the
best antiplatelet therapy for patients. Therapy with aspirin following stroke reduced recurrent …

Purpose of review Recurrent stroke after ischemic stroke (IS) or high-risk transient ischemic
attack (TIA) increases morbidity and mortality. Secondary stroke prevention strategies …

Opinion statement In patients with transient ischemic attack (TIA) or ischemic stroke of
noncardiac origin, antiplatelet drugs are able to decrease the risk of stroke by 11% to 15 …

A critical appraisal and clinical application of Diener HC, Bogousslavsky J, Brass LM, et al.
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or …

Ischaemic stroke and other atherothrombotic events substantially increase the medico-
economic burden because of their high treatment costs and long-lasting disabilities with …